Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: Results from COMPARZ, a randomized controlled trial Academic Article uri icon

Overview

MeSH Major

  • Antigens, CD274
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

abstract

  • Increased tumor cell PD-L1, or PD-L1 plus tumor CD8-positive T-cell counts, were associated with shorter survival in patients with metastatic RCC receiving VEGF-targeted agents. These findings may have implications for future design of randomized clinical trials in advanced RCC.

publication date

  • March 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-14-1993

PubMed ID

  • 25538263

Additional Document Info

start page

  • 1071

end page

  • 7

volume

  • 21

number

  • 5